利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

25 条记录 (耗时 0.023 秒)

    Method and apparatus for impeding sediment deposition in harbors and navigation channels
    1.
    发明授权
    Method and apparatus for impeding sediment deposition in harbors and navigation channels 失效
    阻碍海港和导航通道沉积物沉积的方法和装置

    公开(公告)号：US4560304A

    公开(公告)日：1985-12-24

    申请号：US513865

    申请日：1983-07-14

    申请人： Scott A. Jenkins ,  Joseph B. Sparks

    发明人： Scott A. Jenkins ,  Joseph B. Sparks

    IPC分类号： E02B3/02 ,  E02B3/04 ,  E02B8/02

    CPC分类号： E02B3/02 ,  E02B3/04

    摘要： A buoyant high aspect ratio delta wing having an inverted airfoil shape for producing a downward lift force is anchored at a negative angle of attack adjacent the bottom of a waterway having a current. The net vertical deflection and turbulent trailing wake generated as the water flows past the wing prevents sediments from depositing on the bottom of the waterway for a predetermined distance downstream of the wing. Cascading arrays of such wings may be anchored in succession along the waterway to resuspend sediments and thereby maintain sufficient water depth for navigation while avoiding the cost and environmental drawbacks of dredging.

    摘要翻译： 具有用于产生向下提升力的倒置翼型形状的浮力高纵横比三角翼被固定在邻近具有电流的水道底部的负迎角。 当水流过机翼时，产生的净垂直偏转和湍流尾迹可防止沉积物沉积在水道底部距机翼下游预定的距离。 这种翼的级联阵列可以沿着水道连续锚定以重悬沉积物，从而保持足够的导航水深，同时避免疏浚的成本和环境缺陷。

    Physiochemically controlled scour jet array system
    3.
    发明授权
    Physiochemically controlled scour jet array system 失效
    生理控制冲刷喷射阵列系统

    公开(公告)号：US4506686A

    公开(公告)日：1985-03-26

    申请号：US584834

    申请日：1984-02-29

    申请人： James A. Bailard ,  Scott A. Jenkins

    发明人： James A. Bailard ,  Scott A. Jenkins

    IPC分类号： B05B12/12 ,  B08B3/08 ,  B08B17/00 ,  E02B3/02 ,  B63B59/04 ,  G05D21/00

    CPC分类号： E02B3/023 ,  B05B12/12 ,  B08B17/00 ,  B08B3/08 ,  Y10T137/0801 ,  Y10T137/2509

    摘要： The scour jet array system includes a pump, both fresh water and surface er intakes, an automatic water mixing valve, a chemical buffer injector, a water heater, a series of scour jets with control valves, and a central control system.The control system senses the beginning of ebb tide for starting an initial scour jet, and as each jet scours the freshly deposited mud from the area, temperature, salinity and pH of the surface suction intake water are measured to determine the amount of fresh water injection, chemical buffer injection, water heating and duty cycle time in order to minimize the energy required to scour the sediments from the area.

    摘要翻译： 冲洗喷射阵列系统包括一个泵，包括淡水和地表进水口，自动水混合阀，化学缓冲注射器，热水器，一系列具有控制阀的冲洗喷嘴和中央控制系统。 控制系统检测开始初始冲刷射流的起始潮，并且当每个喷射器从该区域冲洗新沉积的泥浆时，测量表面吸入水的温度，盐度和pH值以确定淡水注入量 ，化学缓冲液注入，水加热和占空比时间，以便最小化从该地区冲洗沉积物所需的能量。

    Nanoparticulate and Controlled Release Compositions Comprising Aryl-Heterocyclic Compounds
    4.
    发明申请
    Nanoparticulate and Controlled Release Compositions Comprising Aryl-Heterocyclic Compounds 审中-公开
    包含芳基杂环化合物的纳米微粒和控制释放组合物

    公开(公告)号：US20110008435A1

    公开(公告)日：2011-01-13

    申请号：US11672263

    申请日：2007-02-07

    申请人： John G. Devane ,  Paul Stark ,  Niall M.M. Fanning ,  Gurvinder Singh Rekhi ,  Scott A. Jenkins ,  Gary Liversidge

    发明人： John G. Devane ,  Paul Stark ,  Niall M.M. Fanning ,  Gurvinder Singh Rekhi ,  Scott A. Jenkins ,  Gary Liversidge

    IPC分类号： A61K9/14 ,  A61K31/496 ,  A61P25/18

    CPC分类号： A61K9/5084

    摘要： The present invention provides a composition comprising ziprasidone useful in the treatment and prevention of schizophrenia and similar psychiatric disorders. In one embodiment, the composition comprises nanoparticulate particles comprising ziprasidone and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a patient, delivers ziprasidone in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions, and to methods for the treatment and prevention of schizophrenia and similar psychiatric disorders.

    摘要翻译： 本发明提供一种包含齐拉西酮的组合物，其可用于治疗和预防精神分裂症和类似的精神障碍。 在一个实施方案中，组合物包含包含齐拉西酮和至少一种表面稳定剂的纳米颗粒颗粒。 纳米颗粒具有小于约2000nm的有效平均粒度。 在另一个实施方案中，组合物包含改性释放组合物，其在给予患者时以双峰，多峰或连续方式递送齐拉西酮。 本发明还涉及含有这些组合物的剂型，以及治疗和预防精神分裂症和类似精神障碍的方法。

    Nanoparticulate and Controlled Release Compositions Comprising Cyclosporine
    6.
    发明申请
    Nanoparticulate and Controlled Release Compositions Comprising Cyclosporine 失效
    包含环孢菌素的纳米颗粒和对照释放组合物

    公开(公告)号：US20080124389A1

    公开(公告)日：2008-05-29

    申请号：US11568692

    申请日：2006-04-12

    申请人： Scott A. Jenkins ,  Gary Liversidge

    发明人： Scott A. Jenkins ,  Gary Liversidge

    IPC分类号： A61K9/50 ,  A61K31/395 ,  A61K9/14

    CPC分类号： A61K9/5084 ,  A61K9/14 ,  A61K9/1676 ,  A61K9/5078 ,  A61K31/395

    摘要： The present invention is directed to a composition comprising a nanoparticulate cyclosporine having improved bioavailability. The nanoparticulate cyclosporine particles of the composition have an effective average particle size of less than about 2000 nm in diameter and are useful in the prevention and treatment of organ transplant rejection and autoimmune diseases such as psoriasis, rheumatoid arthritis, and other related diseases. The invention also relates to a controlled release composition comprising a cyclosporine or a nanoparticulate cyclosporine that in operation delivers the drug in a pulsed or bimodal manner for the prevention and treatment of organ transplant rejection and autoimmune diseases such as psoriasis, rheumatoid arthritis, and other related diseases.

    摘要翻译： 本发明涉及包含具有改善的生物利用度的纳米颗粒环孢霉素的组合物。 组合物的纳米颗粒环孢菌素颗粒具有直径小于约2000nm的有效平均粒度，并且可用于预防和治疗器官移植排斥和自身免疫性疾病如牛皮癣，类风湿性关节炎和其它相关疾病。 本发明还涉及包含环孢菌素或纳米颗粒环孢菌素的控释组合物，其在操作中以脉冲或双峰方式递送药物以预防和治疗器官移植排斥和自身免疫性疾病如牛皮癣，类风湿性关节炎和其它相关的 疾病

    Nanoparticulate and controlled release compositions comprising nilvadipine
    9.
    发明申请
    Nanoparticulate and controlled release compositions comprising nilvadipine 审中-公开
    包含尼伐地平的纳米颗粒和控释组合物

    公开(公告)号：US20100247636A1

    公开(公告)日：2010-09-30

    申请号：US11479013

    申请日：2006-06-30

    申请人： John G. Devane ,  Paul Stark ,  Niall M.M. Fanning ,  Gurvinder Singh Rekhi ,  Scott A. Jenkins ,  Gary Liversidge

    发明人： John G. Devane ,  Paul Stark ,  Niall M.M. Fanning ,  Gurvinder Singh Rekhi ,  Scott A. Jenkins ,  Gary Liversidge

    IPC分类号： A61K9/48 ,  A61K31/4422 ,  A61K9/14 ,  A61K9/50 ,  A61K9/26 ,  A61K9/22 ,  A61P9/12 ,  A61P9/00

    CPC分类号： A61K9/5026 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/192 ,  A61K31/485

    摘要： The present invention provides a composition comprising nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, useful in the treatment and prevention of hypertension or related cardiovascular disorders. In one embodiment, the composition comprises nanoparticulate particles comprising nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a patient, delivers nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions, and to methods for the treatment and prevention of hypertension or related cardiovascular disorders.

    摘要翻译： 本发明提供一种组合物，其包含可用于治疗和预防高血压或相关心血管疾病的尼伐地平或其盐，衍生物，前药或多晶型物。 在一个实施方案中，组合物包含包含尼伐地平或其盐，衍生物，前药或多晶型物和至少一种表面稳定剂的纳米颗粒颗粒。 纳米颗粒具有小于约2000nm的有效平均粒度。 在另一个实施方案中，组合物包含改性释放组合物，其在给予患者时以双峰，多峰或连续方式递送尼伐地平或其盐，衍生物，前药或多晶型物。 本发明还涉及含有这种组合物的剂型，以及治疗和预防高血压或相关心血管疾病的方法。

    NANOPARTICULATE FORMULATIONS OF MODAFINIL
    10.
    发明申请
    NANOPARTICULATE FORMULATIONS OF MODAFINIL 审中-公开
    MODAFINIL的纳米制剂配方

    公开(公告)号：US20080317843A1

    公开(公告)日：2008-12-25

    申请号：US11776770

    申请日：2007-07-12

    申请人： Scott A. Jenkins ,  Gary Liversidge ,  David Manser

    发明人： Scott A. Jenkins ,  Gary Liversidge ,  David Manser

    IPC分类号： A61K9/48 ,  A61K31/165 ,  A61K9/14 ,  A61P25/00 ,  A61K9/00

    CPC分类号： A61K9/145 ,  A61K9/146

    摘要： The present invention is directed to compositions comprising a nanoparticulate modafinil compositions, or a salt(s), or an enantiomer(s), or a prodrug(s), or a polymorph(s) or derivative thereof, having improved bioavailability. The nanoparticulate modafinil composition formulation particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of dyssomnias, including but not limited to, narcolepsy, chronic fatigue, eating disorders, compulsive behaviors, ADHD, addictions, substance abuse, sleepiness, nervous system diseases, conditions, syndromes, and symptoms and related diseases, conditions, and symptoms.

    摘要翻译： 本发明涉及包含具有改善的生物利用度的纳米微粒莫达非尼组合物或其一种或多种或多种或多种或多种或多种或多种或多种形式的衍生物的组合物。 组合物的纳米微粒莫达非尼组合物制剂颗粒具有小于约2000nm的有效平均粒度，并且可用于治疗睡眠障碍，包括但不限于发作性睡病，慢性疲劳，进食障碍，强迫行为，ADHD，成瘾 ，药物滥用，嗜睡，神经系统疾病，病症，综合征，症状及相关疾病，病症和症状。